Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Summary

This is a Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib. Phase I of the study will determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of TAK-659 and Ixazomib. During the phase I, dose escalation will be conducted according to a standard 3+3 dose escalation schema, and up to 18 response-evaluable patients will be enrolled. Phase II of the study will evaluate the efficacy of the combination by measuring the overall response rate (ORR).

Timeline

Start

2019-09-20

Primary completion

2021-09-22

Completion

2022-02-23

Publications

• Pasupuleti SK, Rangaraju S, Layer J, Padam KSR, Cripe LD, Sayar H, Sargent KJ, Weisenbach J, Konig H, Salman H, Ramdas B, Palam LR, Mayo LD, Khan I, Dave UP, Boswell HS, Kapur R. FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by beta-catenin, SQSTM1 and NRF2 in AML. NPJ Precis Oncol. 2026 Feb 26;10(1):168. doi: 10.1038/s41698-026-01332-1.

Drugs

Indications